Date: 2011-01-17
Type of information: Production agreement
Compound: Traumakine® (FP-1201- recombinant human interferon beta-1a (IFN-beta 1a)
Company: Faron Pharmaceuticals Ltd (Finland) Rentschler Biotechnologie GmbH (Germany)
Therapeutic area: Respiratory diseases
Type agreement: Manufacturing
Supply
Production
Action mechanism:
Disease: prevention of vascular leakage in patients with acute lung injuries (ALI) and its more severe form acute respiratory distress syndrome (ARDS)
Details: Rentschler will become the sole global manufacturer of IFN-beta 1a for Faron and also manufacture Faron’s proprietary bulk drug product. Traumakine® is formulated so that it is stable at room temperature and readily available for critical care doctors at intensive treatment units. Traumakine® is meant to prevent vascular leakage in patients with acute lung injuries (ALI) and its more severe form ARDS.
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
